NewsEvents

Your Yourlocation: Home > Tiotropium bromide(136310-93-5) inhalation agent in the treatment of stable moderate to severe COPD patients

OBJECTIVE: To study the clinical efficacy of tiotropium bromide(136310-93-5) inhalers in the treatment of moderate to severe COPD patients.

Methods: Sixty patients with moderate to severe COPD were selected and randomly divided into control group (30 cases) and observation group (30 cases) under the control of patients' informed consent. The patients in the control group were treated with conventional drug therapy. The scores of lung function, blood gas analysis index, dyspnea score, quality of life score and number of adverse reactions were compared between the two groups after 10 weeks of treatment with tiotropium bromide(136310-93-5) inhaler.

Results: After 10 weeks of treatment, the lung function index, blood gas analysis index, dyspnea score and quality of life score of the two groups were statistically significant (P <0.05), the observation group was superior to the control group; the difference was not statistically significant (P> 0.05).

Conclusion: In the course of clinical treatment of patients with severe COPD, it should be treated with tiotropium bromide(136310-93-5) inhaler, which can significantly improve the clinical curative effect and not increase the adverse reaction.

Address: TEL:0531-82375879 Tiotropium Bromide
© Copyright(C)2014 JINAN DEXINJIA BIO & TECH CO., LTD All Rights Reserved